AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31471400 — intervention group
Group type: EXPERIMENTAL
Intervention: Complication rate
Number of subjects: 110
Study 29991814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaping with nicotine
Number of subjects: 25
Study 29991814 — intervention group
Group type: COMPARATOR
Intervention: Sham vaping
Number of subjects: 25
Study 29991814 — intervention group
Group type: COMPARATOR
Intervention: Vaping without nicotine
Number of subjects: 25
Study 26567260 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry state
Number of subjects: 78
Study 26567260 — intervention group
Group type: COMPARATOR
Intervention: Satiated state (after sweet lunch)
Number of subjects: 78
Study 26567260 — intervention group
Group type: COMPARATOR
Intervention: Satiated state (after savory lunch)
Number of subjects: 78
Study 23808817 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nutrition care (telephone dietary counselling for up to 100 days post-transplantation)
Number of subjects: 37
Study 23808817 — intervention group
Group type: COMPARATOR
Intervention: Usual nutrition care (no further nutrition support after hospital discharge)
Number of subjects: 37
Study 22595385 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance (PosFB) group (median 849 ml, IQR 328 - 1,552 ml, n = 19)
Number of subjects: 90
Study 22595385 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive fluid balance (highPosFB) group (n = 10)
Number of subjects: 90
Study 22595385 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive fluid balance (highPosFB) group
Number of subjects: 90
Study 22595385 — intervention group
Group type: COMPARATOR
Intervention: Negative fluid balance (NegFB) group (median -1,221 ml, IQR -1,974 to -653 ml, n = 71)
Number of subjects: 90
Study 19944357 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1587
Study 19944357 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1587
Study 19944357 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1587
Study 17715208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 20 mg orally twice daily for 7 days
Number of subjects: 0
Study 17715208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15494456 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg recombinant human TSH (rhTSH)
Number of subjects: 63
Study 15494456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 12403289 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational strategy including dissemination of evidence-based guidelines via a problem-based interactive workshop facilitated by an opinion leader and a laminated algorithm and guidelines.
Number of subjects: 62
Study 12403289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 62
Study 10546016 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 54
Study 10546016 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 54
Study 10546016 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 54
Study 8703492 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted controlled blood reperfusion (Group A)
Number of subjects: 34
Study 8703492 — intervention group
Group type: COMPARATOR
Intervention: No leukocyte depletion (Group B)
Number of subjects: 34
Study 8703492 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted controlled blood reperfusion (Group C)
Number of subjects: 34
Study 8703492 — intervention group
Group type: COMPARATOR
Intervention: No leukocyte depletion (Group D)
Number of subjects: 34
Study 2110064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 110
Study 2110064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 477470 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylumbelliferone (hymecromone)
Number of subjects: 50
Study 30896330 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural pain reliever
Number of subjects: 1125
Study 30896330 — intervention group
Group type: COMPARATOR
Intervention: Experimental condition with rational appeal
Number of subjects: 1125
Study 29200411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclol 25 mg three times daily
Number of subjects: 168
Study 29200411 — intervention group
Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine 456 mg three times daily
Number of subjects: 168
Study 24777702 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device with heel support and vibrating device for 1 week
Number of subjects: 144
Study 24777702 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with only a CPM device
Number of subjects: 144
Study 23801836 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 200
Study 23801836 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-fentanyl
Number of subjects: 200
Study 21730925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal atropine 100 µg
Number of subjects: 204
Study 21730925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine 100 µg
Number of subjects: 204
Study 21730925 — intervention group
Group type: COMPARATOR
Intervention: Saline only (control group)
Number of subjects: 204
Study 19998580 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (70 mg alendronate sodium)
Number of subjects: 122
Study 19998580 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (70 mg alendronate sodium)
Number of subjects: 122
Study 17518171 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with metamizole and tramadol
Number of subjects: 50
Study 17518171 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion by elastomeric pump of the same analgesic solution (metamizole and tramadol)
Number of subjects: 50
Study 15595587 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) suxamethonium
Number of subjects: 30
Study 15595587 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg kg(‐1) rocuronium after suxamethonium
Number of subjects: 30
Study 12490125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscularly administered polysaccharide nucleic acid fraction of Bacillus Calmette Guerin (PSN-BCG)
Number of subjects: 2
Study 12490125 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculous therapy and thoracentesis
Number of subjects: 2
Study 10095972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermenstrual bleeding since last menses
Number of subjects: 2625
Study 10095972 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive menstrual flow
Number of subjects: 2625
Study 7806600 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocid capsules 'A' (75 mg)
Number of subjects: 22
Study 7806600 — intervention group
Group type: COMPARATOR
Intervention: Indogesic tablets 'B' (75 mg)
Number of subjects: 22
Study 2528260 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid (20%)
Number of subjects: 155
Study 2528260 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone (2%)
Number of subjects: 155
Study 989399 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg tybamate
Number of subjects: 0
Study 989399 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg secobarbital
Number of subjects: 0
Study 989399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30482218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Screener Questionnaire (DSQ)
Number of subjects: 656
Study 30482218 — intervention group
Group type: COMPARATOR
Intervention: Automated Self-Administered 24-Hour Recalls for Children (ASA24-Kids)
Number of subjects: 656
Study 28663382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO3) ingestion (9.3 mg/kg body weight)
Number of subjects: 17
Study 28663382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl, 8.8 mg/kg body weight)
Number of subjects: 17
Study 25625260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (starting at 300 µg kg·min) with oxygen via nasal cannula
Number of subjects: 150
Study 25625260 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane with 70% N2O in oxygen delivered via LMA
Number of subjects: 150
Study 23506279 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (soft tissue massage for 60 seconds)
Number of subjects: 38
Study 23506279 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (crowns of the mandibular premolar teeth massaged)
Number of subjects: 38
Study 21392690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Number of subjects: 41
Study 21392690 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 41
Study 19046094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (2 capsules of Nature Made antioxidants 2 hours before, and 2 and 8 hours after ESWL)
Number of subjects: 120
Study 19046094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (2 capsules of antioxidants at 2 and 8 hours after ESWL)
Number of subjects: 120
Study 19046094 — intervention group
Group type: COMPARATOR
Intervention: Control (no antioxidants, n=39)
Number of subjects: 120
Study 16612143 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ciclopiroxolamine cream applied twice daily for 28 days
Number of subjects: 50
Study 16612143 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 28 days
Number of subjects: 50
Study 14702997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued participants
Number of subjects: 68
Study 14702997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued participants with low computer experience
Number of subjects: 68
Study 14702997 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly experienced participants
Number of subjects: 68
Study 14702997 — intervention group
Group type: COMPARATOR
Intervention: Control (nonfatigued) participants
Number of subjects: 68
Study 10780140 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese with medical information explaining the obesity
Number of subjects: 184
Study 10780140 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese
Number of subjects: 184
Study 10780140 — intervention group
Group type: COMPARATOR
Intervention: Average-weight
Number of subjects: 184
Study 10780140 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-sex target child
Number of subjects: 184
Study 9060219 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine schedule II (three doses of 500 mg)
Number of subjects: 120
Study 9060219 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (all schedules)
Number of subjects: 120
Study 1900485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone (150 mg/d)
Number of subjects: 52
Study 1900485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6401379 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g L-lysine orally
Number of subjects: 0
Study 6401379 — intervention group
Group type: COMPARATOR
Intervention: No lysine load or other amino acids (tryptophan or threonine)
Number of subjects: 0
Study 6401379 — intervention group
Group type: COMPARATOR
Intervention: Undernourished subjects
Number of subjects: 0
Study 6401379 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation of undernourished subjects
Number of subjects: 0
Study 31542291 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic or silver shunts
Number of subjects: 0
Study 31542291 — intervention group
Group type: COMPARATOR
Intervention: Standard ventriculoperitoneal shunts
Number of subjects: 0
Study 29521263 — intervention group
Group type: EXPERIMENTAL
Intervention: Manosar® (D-mannose 2 g, 24h prolonged release, associated with Proanthocyanidin (PAC) 140 mg)
Number of subjects: 93
Study 29521263 — intervention group
Group type: COMPARATOR
Intervention: PAC (240 mg)
Number of subjects: 93
Study 29521263 — intervention group
Group type: EXPERIMENTAL
Intervention: Manosar®
Number of subjects: 93
Study 29521263 — intervention group
Group type: COMPARATOR
Intervention: PAC
Number of subjects: 93
Study 29521263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 28660416 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections
Number of subjects: 46
Study 28660416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26181707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Number of subjects: 100
Study 26181707 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (RTV)
Number of subjects: 100
Study 24143917 — intervention group
Group type: EXPERIMENTAL
Intervention: High current intensity group
Number of subjects: 0
Study 24143917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low current intensity group
Number of subjects: 0
Study 24143917 — intervention group
Group type: COMPARATOR
Intervention: Mosapride citrate control group
Number of subjects: 0
Study 22238838 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache presence
Number of subjects: 1073
Study 22238838 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache among Blacks
Number of subjects: 1073
Study 22238838 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache among Caucasians
Number of subjects: 1073
Study 22238838 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depressive symptoms
Number of subjects: 1073
Study 18629725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of concern about post-cessation weight gain
Number of subjects: 412
Study 18629725 — intervention group
Group type: COMPARATOR
Intervention: High level of concern about post-cessation weight gain
Number of subjects: 412
Study 16838818 — intervention group
Group type: COMPARATOR
Intervention: drugs only (nicotine replacement therapy patch, nasal spray, inhaler, and Zyban)
Number of subjects: 393
Study 16838818 — intervention group
Group type: EXPERIMENTAL
Intervention: drugs and counseling (drugs and proactive telephone counseling)
Number of subjects: 393
Study 16838818 — intervention group
Group type: EXPERIMENTAL
Intervention: drugs if counseling (drugs conditional on enrollment in counseling)
Number of subjects: 393
Study 14740589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral interpleural analgesia (IP) using bupivacaine 0.5% (0.8 mg/kg) and 2 mg morphine diluted to 50 ml saline for each side
Number of subjects: 30
Study 14740589 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (EP) using the same mixture diluted in 20 ml saline injected in the epidural space (L2-3)
Number of subjects: 30
Study 10936119 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg bid
Number of subjects: 18
Study 10936119 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microg bid
Number of subjects: 18
Study 10936119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9010086 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Gd-DTPA MRI
Number of subjects: 0
Study 9010086 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiograms
Number of subjects: 0
Study 7956274 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor receptor antagonist (BN 52021) 120 mg intravenously every 12 hrs for 4 days
Number of subjects: 262
Study 7956274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 7956274 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor receptor antagonist (BN 52021)
Number of subjects: 262
Study 3677280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg IV)
Number of subjects: 7
Study 3677280 — intervention group
Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 7
Study 29351097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate epidural bolus (300 ml/h)
Number of subjects: 210
Study 29351097 — intervention group
Group type: COMPARATOR
Intervention: Low-rate epidural bolus (100 ml/h)
Number of subjects: 210
Study 27027886 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 27027886 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study 24419306 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional awareness training (EMT) in addition to standard symptom‐oriented medical treatment; included two emotion awareness training sessions and daily emotion recording over 20 months.
Number of subjects: 100
Study 24419306 — intervention group
Group type: COMPARATOR
Intervention: Standard symptom‐oriented medical treatment (MT group) only.
Number of subjects: 100
Study 24419306 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional awareness training (EMT) in addition to standard symptom‐oriented medical treatment.
Number of subjects: 100
Study 24628789 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 booster vaccine given at Month 6
Number of subjects: 1206
Study 24628789 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 booster vaccine given at Month 12
Number of subjects: 1206
Study 24628789 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 booster vaccine given at Month 36
Number of subjects: 1206
Study 24628789 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 heterologous booster vaccination
Number of subjects: 1206
Study 24628789 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 booster vaccine
Number of subjects: 1206
Study 22459310 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 9376
Study 22459310 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 9376
Study 20056923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular care
Number of subjects: 123
Study 20056923 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 123
Study 17608677 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 64
Study 17608677 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany
Number of subjects: 64
Study 17608677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 64
Study 17608677 — intervention group
Group type: COMPARATOR
Intervention: Pulp Canal Sealer (EWT)
Number of subjects: 64
Study 17608677 — intervention group
Group type: EXPERIMENTAL
Intervention: Endométhasone
Number of subjects: 64
Study 16254583 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged French volunteers (aged 55-70 years)
Number of subjects: 387
Study 16254583 — intervention group
Group type: COMPARATOR
Intervention: Italian elderly volunteers (aged 70-85 years)
Number of subjects: 387
Study 16254583 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged population
Number of subjects: 387
Study 16254583 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell zinc
Number of subjects: 387
Study 12383572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 20 microg/kg/min intravenously)
Number of subjects: 29
Study 12383572 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 to 2 mg/kg intravenously)
Number of subjects: 29
Study 10420746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (0.25-0.50 mg daily for 1.5-2 months)
Number of subjects: 108
Study 10420746 — intervention group
Group type: COMPARATOR
Intervention: Control group (ramipril-untreated patients)
Number of subjects: 108
Study 8976498 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine administration
Number of subjects: 4
Study 8976498 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicotine)
Number of subjects: 4
Study 1441879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally approximately 100 min before anaesthesia and three times daily for the first 2 postoperative days
Number of subjects: 48
Study 1441879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1441879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 48
Study 3969351 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 0
Study 3969351 — intervention group
Group type: COMPARATOR
Intervention: No phototherapy (Control)
Number of subjects: 0
Study 31571712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 500 mg/day
Number of subjects: 60
Study 31571712 — intervention group
Group type: COMPARATOR
Intervention: Propranolol SR 40 mg/day
Number of subjects: 60
Study 29762864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate‐umeclidinium‐vilanterol (100 μg/62.5 μg/25 μg; Ellipta inhaler)
Number of subjects: 74
Study 29762864 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol (400 μg/12 μg; Turbuhaler)
Number of subjects: 74
Study 26681720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 4718
Study 26681720 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4718
Study 26681720 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 4718
Study 25288624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial PCL reconstruction with hamstring autograft
Number of subjects: 66
Study 25288624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial inlay PCL reconstruction with patellar tendon autograft
Number of subjects: 66
Study 22251419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 mcg, twice daily for 36 weeks
Number of subjects: 522
Study 19926151 — intervention group
Group type: EXPERIMENTAL
Intervention: REFLECT statement for livestock and food safety
Number of subjects: 24
Study 19926151 — intervention group
Group type: COMPARATOR
Intervention: CONSORT checklist
Number of subjects: 24
Study 18062107 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM/P-15 hydrogel
Number of subjects: 19
Study 18062107 — intervention group
Group type: COMPARATOR
Intervention: ABM/P-15 particulate
Number of subjects: 19
Study 16225718 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach
Number of subjects: 30
Study 16225718 — intervention group
Group type: COMPARATOR
Intervention: Midline approach
Number of subjects: 30
Study 16225718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 30